CXCL12 and prostate carcinoma: In prostate cancer, estrogen-induced CAF-derived CXCL12 binds to CXCR4 and enhances mast cell proliferation, migration, and inflammatory cytokine secretion, thus exhibiting oncogenic effects (Ellem et al., 2014).